Exelixis Generated 10 IND Compounds and Received over $235 Million
SOUTH SAN FRANCISCO, Calif., June 27 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that the company and GlaxoSmithKline, Inc. (NYSE: GSK) will bring their six-year collaboration to a successful conclusion on October 27, 2008, as scheduled. Under the terms of the collaboration, GSK has the right to select up to two of the compounds in the collaboration for further development and commercialization. GSK previously selected XL880 and will be able to choose one additional compound from among XL184, XL281, XL228, XL820, and XL844. Exelixis will have the right to develop and commercialize compounds not selected by GSK, either alone or in collaboration with partners. As a result of the conclusion of the collaboration, Exelixis' exclusivity obligations will be limited to the compounds selected by GSK. Exelixis will have the right to perform additional discovery, development, and commercialization efforts against any collaboration target or compound that does not infringe upon the intellectual property associated with compounds selected by GSK for further development and commercialization.
"This collaboration represents a successful alliance that has truly
benefited both companies. With the selection of GSK089 (formerly XL880) and
potentially one other compound, GSK has been able to strengthen its
oncology pipeline. I am enthusiastic about the compounds remaining in the
collaboration, and continue to be impressed by Exeli
|SOURCE Exelixis, Inc.|
Copyright©2008 PR Newswire.
All rights reserved